...
首页> 外文期刊>European Heart Journal: The Journal of the European Society of Cardiology >Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: The Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial)
【24h】

Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: The Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial)

机译:稳定的非ST段抬高型心肌梗死中有创血管造影的最佳时机:NSTEMI中的莱比锡即刻与早期和晚期PercutaneouS冠状动脉介入治疗TriAl的比较(LIPSIA-NSTEMI试验)

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AimsThe optimal timing of intervention in non-ST-elevation myocardial infarction (NSTEMI) remains uncertain. The aim of this multicentre trial was to assess whether an immediate invasive approach is superior to an early invasive or a selective invasive approach with respect to reduction of large infarction. Methods and resultsPatients with NSTEMI were randomized to either an immediate (<2 h after randomization; n = 201), an early (1048 h after randomization; n = 200), or a selective invasive approach with high invasive percentage (n = 201). The primary outcome was the peak creatine kinase (CK)-myocardial band (MB) activity during index hospitalization; key secondary clinical endpoints were the composite of (i) death and non-fatal infarction; (ii) death, non-fatal infarction, and refractory ischaemia; (iii) death, non-fatal infarction, refractory ischaemia, and rehospitalization for unstable angina within 6 months.The median time from randomization to angiography was 1.1 h in the immediate vs. 18.6 h in the early and 67.2 h in the selective invasive group (P< 0.001). There was no significant difference in the peak CK-MB activity between groups. The key secondary clinical endpoints were similar between groups at 6-month follow-up: death and infarction: 21.0 vs. 16.0 vs. 14.5; P = 0.17; death, infarction, refractory ischaemia: 20.9 vs. 21.5 vs. 22.0; P = 0.98; death, infarction, refractory ischaemia, rehospitalization: 26.0 vs. 26.5 vs. 24.5; P = 0.91, respectively. ConclusionsIn NSTEMI patients, an immediate invasive approach does not offer an advantage over an early or a selective invasive approach with respect to large myocardial infarctions as defined by peak CK-MB levels, which is supported by similar clinical outcomes.
机译:目的非ST段抬高型心肌梗死(NSTEMI)的最佳干预时机仍不确定。这项多中心试验的目的是评估就减少大面积梗塞而言,立即侵入性治疗优于早期侵入性治疗还是选择性侵入性治疗。方法和结果将患有NSTEMI的患者随机分为即刻(随机分组后<2 h; n = 201),早期(随机分组后1048 h; n = 200)或高侵入百分比的选择性侵入性方法(n = 201) 。主要结果是在指数住院期间肌酸激酶(CK)-心肌带(MB)活性达到峰值。主要的次要临床终点是(i)死亡和非致命性梗死的综合; (ii)死亡,非致命性梗塞和难治性缺血; (iii)不稳定型心绞痛的死亡,非致命性梗死,难治性局部缺血和再次住院治疗在6个月内。从随机分组到血管造影的平均时间在即刻为1.1 h,在早期为18.6 h,在选择性浸润组为67.2 h (P <0.001)。各组之间的CK-MB活性峰值无显着差异。各组在6个月的随访中主要的次要临床终点相似:死亡和梗塞:21.0 vs. 16.0 vs. 14.5; P = 0.17;死亡,梗塞,难治性缺血:20.9 vs. 21.5 vs. 22.0; P = 0.98;死亡,梗塞,难治性缺血,再住院:26.0 vs. 26.5 vs. 24.5; P分别为0.91。结论在NSTEMI患者中,就峰值CK-MB水平所定义的大型心肌梗塞而言,立即侵入性治疗没有比早期或选择性侵入性治疗更具优势,这在相似的临床结果中得到了支持。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号